Table 1. Description of the study population according to the liver fibrosis status.
Continuous variables are expressed with their median and interquartile range (IQR) for the general population and mean and standard deviation (SD) when categorized by liver fibrosis group.
| General population n = 104 | Patients with F0-2 liver fibrosis n = 80 | Patients with F3-4 liver fibrosis n = 24 | P value | |
|---|---|---|---|---|
| Socio-demographic characteristics | ||||
| Male gender (n, %) | 99 (95.2) | 75 (93.8) | 24 (100) | 0.6 |
| Age, years | 35.8 (32.7–39.6) | 37.1 (6.2) | 36.6 (5.5) | 0.9 |
| BMI, kg/m2 | 19.6 (18.4–21.6) | 20.1 (2.0) | 20.1 (2.3) | 0.8 |
| IV drug use as way of HCV transmission (n, %) | 72 (69.2) | 56 (70) | 16 (66.7) | 0.8 |
| Current or past excessive alcohol consumption (n, %) | 70 (67.3) | 50 (62.5) | 20 (83.3) | 0.04 |
| Current tobacco use (n, %) | 82 (78.9) | 65 (81.3) | 17 (70.8) | 0.3 |
| Current cannabis use (n, %) | 16 (15.4) | 11 (13.8) | 5 (20.8) | 0.5 |
| Current use of any drugs (including injecting) (n, %) | 8 (10.8) | 6 (10.3) | 2 (12.5) | 0.9 |
| Current use of injecting drugs (n, %) | 9 (12.7) | 7 (12.5) | 2 (13.3) | 0.9 |
| Current oral opioid substitution (n, %) | 21 (20.2) | 18 (22.5) | 3 (12.5) | 0.4 |
| HIV characteristics | ||||
| Estimated duration of HIV infection from first screening, years | 6.3 (3.1–7.8) | 6.6 (4.0) | 5.7 (3.8) | 0.4 |
| CD4 nadir, per mm3 | 84 (38–175) | 113 (113.4) | 133 (110.2) | 0.2 |
| Current CD4 count, per mm3 | 504 (361–624) | 521 (210.2) | 471 (159.6) | 0.4 |
| Undetectable HIV-RNA (n, %) | 98 (94.2) | 75 (93.8) | 23 (95.8) | 0.9 |
| Duration of cART, years | 4.3 (4.1–6.0) | 4.2 (1.9) | 3.8 (1.9) | 0.3 |
| Type of ART | ||||
| 2 NNRTI and Nevirapine | 7 (6.7) | 4 (5) | 3 (12.5) | 0.07 |
| 2 NNRTI and Efavirenz- | 91 (87.5) | 73 (91.3) | 18 (75.0) | 0.08 |
| 2 NNRTI and Lopinavir/ritonavir | 6 (5.8) | 3 (3.5) | 3 (12.5) | 0.07 |
| HBsAg positivity (n, %), n = 103 | 13 (12.6) | 9 (11.3) | 4 (12.6) | 0.5 |